ANRO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ANRO is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has encouraging analyst support and a recent Buy initiation from BofA with a $35 target, but the current chart is weak, sentiment from options is only mildly positive, hedge funds are selling, and the latest quarter still shows losses with no revenue growth. Given the user's impatience, this is not the kind of entry I would label a clear buy today; I would wait for a cleaner technical setup or stronger fundamental confirmation.
ANRO is trading at 23.92, below the recent pivot at 24.931 and only slightly above support at 23.595. MACD histogram is negative and expanding, which points to weakening momentum. RSI at 38.1 is neutral-to-soft, not oversold enough to signal a strong rebound. Moving averages are converging, suggesting the stock is in a consolidation phase rather than a confirmed uptrend. Short-term pattern expectations also lean slightly negative, with modeled probability skewed toward small declines over the next day, week, and month.
["BofA initiated coverage with a Buy rating and $35 target on 2026-05-04.", "Earlier analyst commentary continues to highlight ALTO-207 as a potentially differentiated treatment for treatment-resistant depression.", "The company has multiple pipeline catalysts ahead in precision neuropsychiatry, including ALTO-207, ALTO-300, and ALTO-100.", "Cash from the recent financing supports execution through 2029, reducing near-term funding pressure."]
["ALTO-101 failed its Phase 2 primary endpoints, which pressured the stock and reduced confidence in one program.", "Hedge funds are selling, with selling up 159.20% over the last quarter.", "The stock has no recent AI Stock Picker or SwingMax signal.", "The latest quarter still shows negative net income and negative EPS with no revenue growth."]
In Q4 2025, Alto Neuroscience reported no revenue growth, with revenue at 0 and unchanged year over year. Net income was -16.18 million, an improvement of 6.45% YoY, but EPS fell to -0.47, down 17.54% YoY. This is still a loss-making clinical-stage biotech profile, so the latest quarter shows cash-burning operations rather than commercial growth.
Wall Street is mixed but generally constructive. Recent ratings include BofA initiating Buy at $35, H.C. Wainwright reiterating Buy at $50, BTIG at Buy with $28, and JonesResearch at Buy with $44, while Wedbush remains Neutral with a $21 target. The pros view is that the market is undervaluing Alto’s depression-focused pipeline and multiple upcoming catalysts; the cons view is that the ALTO-101 miss is a meaningful setback and the business remains highly dependent on clinical success. Overall, analyst sentiment is bullish-leaning, but not uniformly so.
